semustine has been researched along with Malignant Melanoma in 44 studies
Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)." | 9.05 | Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980) |
| "The nephrotoxicity of semustine (methyl-CCNU) has been studied in 45 adult patients with surgically resected Stage I or II malignant melanoma who received this drug as adjuvant chemotherapy." | 9.05 | Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. ( Fisher, RI; Jensen-Akula, M; Mandard, JC; Micetich, KC, 1981) |
| "Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)." | 9.04 | Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976) |
| "One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU." | 7.67 | Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984) |
| "Cells from a resistant ("Gr II") and a sensitive ("Str") human melanoma xenograft were incubated in vitro with O6-methylguanine for 2 h, subsequently treated with 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea (MeCCNU) for 1 h and then plated in soft agar." | 7.67 | Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells. ( Dempke, W; Nehls, P; Osieka, R; Schmidt, CG; Soll, D; Wandl, U, 1987) |
| "In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma." | 7.67 | Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987) |
| "Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)." | 7.66 | Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982) |
| "One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)." | 5.05 | Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980) |
| "The nephrotoxicity of semustine (methyl-CCNU) has been studied in 45 adult patients with surgically resected Stage I or II malignant melanoma who received this drug as adjuvant chemotherapy." | 5.05 | Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. ( Fisher, RI; Jensen-Akula, M; Mandard, JC; Micetich, KC, 1981) |
| "Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)." | 5.04 | Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976) |
| "One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU." | 3.67 | Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984) |
| "Cells from a resistant ("Gr II") and a sensitive ("Str") human melanoma xenograft were incubated in vitro with O6-methylguanine for 2 h, subsequently treated with 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea (MeCCNU) for 1 h and then plated in soft agar." | 3.67 | Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells. ( Dempke, W; Nehls, P; Osieka, R; Schmidt, CG; Soll, D; Wandl, U, 1987) |
| "In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma." | 3.67 | Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987) |
| "Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)." | 3.66 | Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982) |
| "Human melanoma xenografts in immune-deprived mice have been used to assess the value of the agar diffusion chamber for chemosensitivity testing." | 3.66 | Use of the agar diffusion chamber for the exposure of human tumor cells to drugs. ( Selby, PJ; Steel, GG, 1982) |
| "The therapeutic usefulness of chlorpromazine (CPZ) and caffeine (CAF) in combination with selected nitrosoureas was investigated in mice bearing L1210 leukemia, Lewis lung carcinoma, and B16 melanoma." | 3.66 | Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. ( Dykes, DJ; Laster, WR; Rose, WC; Schabel, FM; Trader, MW, 1978) |
| "Single doses of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea caused transient suppression of [3H]thymidine incorporation into DNA in bone marrow and gastrointestinal mucosa and more prolonged inhibition of such incorporation in B16 melanoma." | 3.65 | Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy. ( Brereton, HD; Bryant, TL; Young, RC, 1975) |
| " Further, both disease staging and drug dosage have been shown to influence cure rates of combined-modality treatment." | 2.35 | Concepts for treatment of micrometastases developed in murine systems. ( Schabel, FM, 1976) |
| " The results imply that dosage scheduling in the treatment of murine melanomas must be individualized." | 1.26 | Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas. ( Hill, GJ; Hill, HZ, 1982) |
| " Dose-response curves were obtained and the surviving fraction at drug levels estimated to be achieved in man was used as a measure of in vitro drug sensitivity." | 1.26 | In vitro chemosensitivity tests on xenografted human melanomas. ( Bateman, AE; Selby, PJ; Steel, GG; Towse, GD, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (95.45) | 18.7374 |
| 1990's | 2 (4.55) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osieka, R | 6 |
| Glatte, P | 4 |
| Pannenbäcker, R | 2 |
| Schmidt, CG | 5 |
| Von Hoff, DD | 1 |
| Amato, DA | 2 |
| Kaufman, JH | 1 |
| Falkson, G | 2 |
| Cunningham, TJ | 2 |
| Kemeny, N | 1 |
| Raina, S | 1 |
| Hill, HZ | 3 |
| Hill, GJ | 3 |
| Rush, BF | 1 |
| Kirkwood, JM | 1 |
| Marsh, JC | 1 |
| Cohen, MH | 1 |
| Schoenfeld, D | 2 |
| Wolter, J | 2 |
| Fisher, RI | 2 |
| Terry, WD | 1 |
| Hodes, RJ | 1 |
| Rosenberg, SA | 1 |
| Makuch, R | 1 |
| Gordon, HG | 1 |
| Fisher, SG | 1 |
| Micetich, KC | 1 |
| Jensen-Akula, M | 1 |
| Mandard, JC | 1 |
| Knost, JA | 1 |
| Reynolds, V | 1 |
| Greco, FA | 1 |
| Oldham, RK | 1 |
| Creagan, ET | 1 |
| Ahmann, DL | 3 |
| Schutt, AJ | 1 |
| Green, SJ | 1 |
| Selby, PJ | 2 |
| Steel, GG | 2 |
| Haedecke, U | 1 |
| Griswold, DP | 2 |
| Corbett, TH | 1 |
| Schabel, FM | 5 |
| Bateman, AE | 1 |
| Towse, GD | 1 |
| Coates, AS | 1 |
| Segelov, E | 1 |
| Livingston, RB | 1 |
| Einhorn, LH | 2 |
| Bodey, GP | 1 |
| Burgess, MA | 1 |
| Freireich, EJ | 1 |
| Gottlieb, JA | 1 |
| Mabel, JA | 1 |
| Merker, PC | 1 |
| Sturgeon, ML | 1 |
| Wodinsky, I | 1 |
| Geran, RI | 1 |
| Furnas, B | 1 |
| Costanza, ME | 1 |
| Nathanson, L | 1 |
| Colsky, J | 1 |
| Regelson, W | 1 |
| Cunningham, T | 1 |
| Sedransk, N | 1 |
| Kokoschka, EM | 1 |
| Luger, T | 1 |
| Micksche, M | 1 |
| Berd, D | 2 |
| Wilson, EJ | 1 |
| Bellet, RE | 2 |
| Mastrangelo, MJ | 2 |
| Miller, CL | 1 |
| Pfaller, M | 1 |
| Weiss, K | 1 |
| Galin, M | 1 |
| Berkelhammer, J | 1 |
| Prehn, RT | 1 |
| Didolkar, MS | 1 |
| Baffi, RR | 1 |
| Catane, R | 1 |
| Kaufman, J | 1 |
| Holyoke, ED | 1 |
| Lee, W | 1 |
| Moore, RP | 1 |
| Wampler, GL | 1 |
| Rose, WC | 1 |
| Trader, MW | 1 |
| Dykes, DJ | 2 |
| Laster, WR | 1 |
| Bisel, HF | 1 |
| Edmonson, JH | 1 |
| Hahn, RG | 1 |
| Eagan, RT | 1 |
| O'Connell, MJ | 1 |
| Frytak, S | 1 |
| Byrne, MJ | 1 |
| Wittes, RE | 1 |
| Hong, WK | 1 |
| Gatchell, L | 1 |
| Krakoff, IH | 1 |
| Golbey, RB | 1 |
| Brereton, HD | 1 |
| Bryant, TL | 1 |
| Young, RC | 1 |
| Luce, JK | 1 |
| Boaziz, C | 1 |
| Breau, JL | 1 |
| Morere, JF | 1 |
| Israël, L | 1 |
| Paietta, E | 1 |
| Papenhausen, P | 1 |
| Ciobanu, N | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 1 |
| Dempke, W | 1 |
| Nehls, P | 1 |
| Wandl, U | 1 |
| Soll, D | 1 |
| Bruckner, H | 1 |
| Guerry, D | 1 |
| Ash, A | 1 |
| Borden, EC | 1 |
| Creech, RH | 1 |
| Savlov, ED | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 1 |
5 reviews available for semustine and Malignant Melanoma
| Article | Year |
|---|---|
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
Concepts for treatment of micrometastases developed in murine systems.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Cricetinae; Cyclop | 1976 |
Nitrosoureas: a review of experimental antitumor activity.
Topics: Animals; Carmustine; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, | 1976 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interl | 1991 |
Methyl-CCNU inclinical cancer therapy.
Topics: Animals; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous | 1974 |
12 trials available for semustine and Malignant Melanoma
| Article | Year |
|---|---|
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
Topics: Caffeine; Chlorpromazine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Melanoma; Nit | 1980 |
Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
Topics: BCG Vaccine; Cell Line; Clinical Trials as Topic; Female; Humans; Male; Melanoma; Mitomycins; Neopla | 1981 |
Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Humans; Kidney; | 1981 |
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymph N | 1982 |
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leuko | 1977 |
Results with methyl-CCNU and DTIC in metastatic melanoma.
Topics: Brain Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dacarbazine; Drug | 1977 |
[Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
Topics: Bacterial Vaccines; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compo | 1978 |
Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cell Line; Cytotoxicity, Immunologic; Drug Therapy, | 1979 |
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug | 1976 |
Nitrosoureas in the management of disseminated malignant melanoma.
Topics: Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; | 1976 |
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Fem | 1976 |
28 other studies available for semustine and Malignant Melanoma
| Article | Year |
|---|---|
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans; | 1983 |
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis | 1984 |
Studies on drug resistance in a human melanoma xenograft system.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Models, Ani | 1984 |
Scheduling of combination chemotherapy for a murine melanoma, with the subrenal capsular assay.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; | 1984 |
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
Topics: Animals; Biological Assay; Biotransformation; Cell Survival; Clone Cells; Dacarbazine; Drug Evaluati | 1983 |
Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
Topics: Animals; Cell Line; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Me | 1982 |
Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Leukopenia; Male; | 1982 |
Use of the agar diffusion chamber for the exposure of human tumor cells to drugs.
Topics: Agar; Animals; Antineoplastic Agents; Cell Survival; Diffusion; Doxorubicin; Drug Evaluation, Precli | 1982 |
[Enhancement of MeCCNU potency (chemosensitization) by misonidazole in a human melanoma xenograft system].
Topics: Animals; Cell Line; Drug Interactions; Female; Humans; Melanoma; Mice; Mice, Nude; Misonidazole; Neo | 1982 |
Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure.
Topics: Animals; Clone Cells; Cyclophosphamide; Drug Resistance; Humans; Leukemia L1210; Melanoma; Mice; Neo | 1981 |
In vitro chemosensitivity tests on xenografted human melanomas.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Hu | 1980 |
Long term response to chemotherapy in patients with visceral metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 1994 |
COMB (cyclophosphamide, oncovin, methyl-CCNU, and bleomycin): a four-drug combination in solid tumors.
Topics: Bleomycin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Drug | 1975 |
Combination chemotherapy against B16 melanoma: bleomycin/vinblastine, bleomycin/cis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cisplatin; Dose-Response Relationship, Drug; | 1978 |
Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
Topics: Adult; Aged; Antibody Formation; Antigens; Dinitrochlorobenzene; Escherichia coli; Female; Hemocyani | 1979 |
Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
Topics: Animals; Cell Count; Dacarbazine; Female; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasm | 1979 |
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Topics: Dacarbazine; Drug Evaluation; Drug Resistance; Humans; Melanoma; Nitrosourea Compounds; Procarbazine | 1977 |
Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.
Topics: Brain Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Pu | 1978 |
Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
Topics: Animals; Caffeine; Carmustine; Chlorpromazine; Drug Synergism; Drug Therapy, Combination; Female; Le | 1978 |
Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
Topics: Bone Marrow; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Met | 1977 |
Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy.
Topics: Animals; Bone Marrow; Cell Division; Depression, Chemical; DNA; DNA, Neoplasm; Gastric Mucosa; Intes | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor.
Topics: Animals; Carmustine; Cell Line; Cells, Cultured; Melanoma; Mice; Neoplasm Transplantation; Neoplasms | 1976 |
Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
Topics: Animals; Caffeine; Chlorpromazine; Drug Resistance; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Tra | 1989 |
Biphenotypic leukemia with unusual chromosomal translocation in a patient treated for melanoma.
Topics: Acute Disease; Adult; Antibodies, Monoclonal; Antigens, Neoplasm; Chromosomes, Human, 1-3; Histocomp | 1986 |
Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Cell Division; Colony-Forming Units Assay; Cross-Linking Re | 1987 |
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1987 |
Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caffeine; Chlorpromazine; DNA | 1986 |